letrozole has been researched along with Dizziness in 2 studies
Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this survey was to compare the effect of letrozole with medroxyprogesterone acetate (MPA) in treatment of simple endometrial hyperplasia to preserve fertility in young women." | 9.17 | Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women. ( Dehghani, A; Dehghani-Tafti, M; Karimi Zarchi, M; Miratashi-Yazdi, A; Tabatabaie, A; Teimoori, S, 2013) |
| "To present the basis of the decision of the Food and Drug Administration to grant accelerated approval for letrozole for extended adjuvant treatment of early-stage breast cancer in postmenopausal women after completion of adjuvant tamoxifen." | 7.73 | Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. ( Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G, 2005) |
| "The aim of this survey was to compare the effect of letrozole with medroxyprogesterone acetate (MPA) in treatment of simple endometrial hyperplasia to preserve fertility in young women." | 5.17 | Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women. ( Dehghani, A; Dehghani-Tafti, M; Karimi Zarchi, M; Miratashi-Yazdi, A; Tabatabaie, A; Teimoori, S, 2013) |
| "To present the basis of the decision of the Food and Drug Administration to grant accelerated approval for letrozole for extended adjuvant treatment of early-stage breast cancer in postmenopausal women after completion of adjuvant tamoxifen." | 3.73 | Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. ( Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tabatabaie, A | 1 |
| Karimi Zarchi, M | 1 |
| Dehghani-Tafti, M | 1 |
| Miratashi-Yazdi, A | 1 |
| Teimoori, S | 1 |
| Dehghani, A | 1 |
| Mann, BS | 1 |
| Johnson, JR | 1 |
| Kelly, R | 1 |
| Sridhara, R | 1 |
| Williams, G | 1 |
| Pazdur, R | 1 |
1 trial available for letrozole and Dizziness
| Article | Year |
|---|---|
Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
Topics: Adult; Antineoplastic Agents, Hormonal; Biopsy; Curettage; Dizziness; Endometrial Hyperplasia; Estra | 2013 |
1 other study available for letrozole and Dizziness
| Article | Year |
|---|---|
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Br | 2005 |